Choroidal Morphology Changes After Aflibercept Therapy in Pachychoroid Neovasculopathy
- Sponsor
- Kim's Eye Hospital
- Study ID
- NCT05662410
- Phase
- PHASE4
- Status
- Completed
Conditions
- Pachychoroid Neovasculopathy
Eligibility Criteria
- Sex
- ALL
- Age
- 50 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Three monthly injections of intravitreal aflibercept — DRUGThree monthly intravitreal injection of aflibercept (2.0mg / 0.05ml) after diagnosis of pathychoroid neovasculopathy.
Study Details
In the present study, investigators attempt to evaluate the short-term, detailed changes in choroidal morphology after three monthly injections of aflibercept in pachychoroid neovasculopathy. The association between these changes and clinical outcomes will be additionally investigated. The primary purpose of this study is to provide reference data regarding the aflibercept-related morphologic changes that implicate structural and functional choroidal alteration, and hence its clinical implications.
Key Dates
- Start date
- Dec 26, 2022
- Status verified
- May 2025
- Primary completion
- May 24, 2024
- Completion
- May 26, 2024
Study Design
- Enrollment
- 30 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Aflibercept treatment groupPatients receiving three monthly aflibercept injections
Primary Outcome Measure
Area of choroidal layer [ Time Frame: Baseline and Week 12 ]